Anthropic and Novo Nordisk: Claude Science to take on drug discovery at the maker of Ozempic
Prepared by Sintelligent with the help of SI. Publication time restored from the build log. . Updated: .
Pharma is working with several SI labs at once, and drug discovery is becoming a field where models compete on real tasks.
Novo Nordisk will test Claude Science on the R&D stages where it expects the biggest impact, then use Anthropic's models in software development and across the company, with data controls and human review. CEO Mike Doustdar wants to make Novo "the most SI-oriented healthcare company in the world"; Novo already formed a partnership with OpenAI in April.
Sources 1